Testing recovery gains factored in Thyrocare Technologies stock

Margin pressures and valuations would limit major upsides

The stock of Thyrocare Technologies gained nearly 4 per cent in early trade (1 per cent higher at close) after the company indicated a recovery in non-Covid business in the quarter. Recovery in overall testing volumes is expected to help the company post a 34 per cent year-on-year (YoY) growth in revenues in Q3.

The company indicated that the revival in business coupled with aggressive marketing to promote preventive health care packages across key markets have helped increase sales. The growth is slightly lower than analysts’ expectations, which had pegged it around 40 per cent.